novo nordisk semaglutide nash Wegovy Gets Green Light for Fatty Liver Disease Novo's trial of weight-loss drug

Aug 14: Biotech company Revance Therapeutics has received its first therapeutic indication for Daxxify (daxibotulinumtoxinA-lanm) for the treatment of cervical dystonia in adults

That dual action is one reason tirzepatide has drawn so much attention in medical weight loss

The human evidence was generated with characterized clinical material

In the future it will be interesting to see whether a single small molecule can target multiple family B GPCR receptors

And then, you probably made some new goals, otherwise called New Years Resolutions. Sound familiar

For some, the medication might lead to initial tiredness as their body adjusts, while others might not experience any fatigue at all